RxDoctor Payments Data

Emily Beckman, APRN

Nurse Practitioner · Louisville, KYNPI 1942665161

Payments from drug & device makers

$4,148in general payments, 2019–2025

Across 192 payments — averaging $21.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$660
  • Biohaven Pharmaceuticals, Inc.$592
  • Pfizer$519
  • Biohaven Pharmaceutical Holding Company Ltd.$344
  • Idorsia Pharmaceuticals US Inc$217
  • plus $686 from 6 others

What the payments were for

  • Food & beverage$4,148100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,148 in reported general payments places this provider in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$34,833
Medicare patients
93
Services billed
523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide106$109,152
EliquisApixaban52$53,561
MounjaroTirzepatide45$48,606
WegovySemaglutide20$26,179
JardianceEmpagliflozin13$21,713
FarxigaDapagliflozin Propanediol23$20,775
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$16,217
XareltoRivaroxaban21$12,675
JanuviaSitagliptin Phosphate15$11,663
Breo ElliptaFluticasone/Vilanterol18$7,268
AirsupraAlbuterol Sulfate/Budesonide12$5,545
Albuterol Sulfate HfaAlbuterol Sulfate61$2,868
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,729
Rosuvastatin Calcium127$2,203
Atorvastatin Calcium227$1,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$660$135,331126 claims
PfizerEliquis$519$53,56152 claims
Lilly USA, LLCMounjaro$196$48,60645 claims
AstraZenecaFarxiga, Airsupra$1,130$26,32035 claims
GSKTrelegy Ellipta, Breo Ellipta$100$23,48544 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →